PIQ.AX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 01:58):

Stats
Today's Volume	156 209
Average Volume	326 089
Market Cap	142.67M
EPS	$0 ( 2024-02-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-21.80
ATR14	$0.00700 (0.64%)

Proteomics International Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Proteomics International Financials

Annual	2023
Revenue:	$730 340
Gross Profit:	$-1.62M (-221.14 %)
EPS:	$-0.0535

Q2	2023
Revenue:	$541 715
Gross Profit:	$-3.15M (-581.43 %)
EPS:	$-0.0307

Q4	2023
Revenue:	$299 202
Gross Profit:	$-3.74M (-1 248.42 %)
EPS:	$-0.0182

Q3	2023
Revenue:	$1.21M
Gross Profit:	$605 033 (50.13 %)
EPS:	$-0.0109

Financial Reports:

No articles found.

Proteomics International

Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute and the Janssen Research & Development for the research of diabetic kidney disease treatment; and partnership with QIMR Berghofer Medical Research Institute for the detection of oesophageal adenocarcinoma. The company was founded in 2001 and is based in Perth, Australia.